Drug intelligence / Profile preview

NGM708

Development stage: Unknown
Lead developer: NGM Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NGM708 is an investigational monoclonal antibody developed by NGM Biopharmaceuticals. It is designed as a novel immunotherapy targeting the immune checkpoint receptor ILT3 (also known as LILRB4). The drug acts as an antagonist of ILT3, aiming to reprogram myeloid cells in the tumor microenvironment and enhance anti-tumor immune responses. By blocking ILT3, NGM708 seeks to overcome myeloid-driven immunosuppression that can limit the effectiveness of other cancer immunotherapies. As of mid-2025, it is being evaluated in early-phase clinical trials for advanced solid tumors.

Other names: NGM708NGM-708NGM 708

Targets

LILRB4

Beyond the preview

Go deeper on NGM708.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGM708.

Explore the full profile